Mangoceuticals clarifies GLP-1 weight-management program launch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/6/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
November 13, 2025 7:37 PM UTCDallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (Mangoceuticals or the Company) is issuing the following clarification regarding its press release issued earlier this morning titled Mangoceuticals Partners with Eli Lilly and Novo Nordisk.
The newly launched Mangoceuticals weight-management programs MangoRx Direct and PeachesRx Direct are licensed and approved to issue, through a third-party provider, valid prescriptions for FDA-approved branded GLP-1 medications, including, when medically appropriate, Zepbound® from Eli Lilly and Wegovy® from Novo Nordisk. These programs allow Mangoceuticals patients to access, for the first time,... More
